180 Life Sciences Corp. (ATNF)
| Market Cap | 4.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.18M |
| Shares Out | 5.19M |
| EPS (ttm) | -15.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,503 |
| Open | 0.8700 |
| Previous Close | 0.8601 |
| Day's Range | 0.8500 - 0.9049 |
| 52-Week Range | 0.6580 - 17.7500 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About ATNF
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of... [Read more]
Financial Performance
Financial StatementsNews
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules
PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international ...
180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules
PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requ...
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international e...
180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration
PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant.
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective i...
This biotech stock soared a whopping 900% on Wednesday: here's why
180 Life Sciences Corp (NASDAQ: ATNF), a biotech firm, saw its shares skyrocket by 900% on Wednesday following the acquisition of a blockchain-enabled platform. This strategic move marks a significant...
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Offi...
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has...
180 Life Sciences Corp. - Corporate Updates
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet PALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Scien...
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effect...
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced...
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qual...
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 202...
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its ou...
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as fi...
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process ...
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing o...
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing o...
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Do...
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
PALO ALTO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing ...
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
Priced At-The-Market Under Nasdaq Rules Priced At-The-Market Under Nasdaq Rules
180 Life Sciences Announces Presentation at the Gordon Conference
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected t...
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application
PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (...
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across Engla...
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease
PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for...